Adult Infectious Diseases Fellowship

Practice session

A clinical fellow is designing an aminoglycoside dosing regimen (e.g., amikacin or gentamicin) for a patient with severe Gram-negative bacteremia. Which pharmacokinetic and pharmacodynamic (PK/PD) index best correlates with bacterial killing efficacy for aminoglycosides, and what pharmacological property supports extended-interval (once-daily) dosing?

Loading your practice session…